Bellicum Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Bellicum Pharmaceuticals

11/08/2022 22:22

* Bellicum Pharmaceuticals Inc  BLCM.OQ  reported a
quarterly
adjusted loss of 13 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 69 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Bellicum Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 13 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Bellicum Pharmaceuticals Inc shares had risen by 15.0%
this
quarter and lost 8.1% so far this year.
    * The company reported a quarterly loss of $4 million.
    * Wall Street's median 12-month price target for Bellicum
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 09:22 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.69          -0.13          Beat
 Mar. 31 2022      -0.67          -0.25          Beat
 Dec. 31 2021      -0.40          0.11           Beat
                                  0.07